Market Research Logo

Global GERD Market 2016-2020

Global GERD Market 2016-2020

About GERD Drugs

Gastroesophageal reflux disease (GERD) is a chronic digestive disorder that affects the lower esophageal sphincter (LES), the ring of muscle between the stomach and esophagus. It occurs when acidic stomach juices, or food and fluids flow back up into the food pipe (esophagus). The backwash irritates the lining of the esophagus and causes GERD. It affects all ages from infants to older adults. The symptoms of GERD include difficulty while swallowing (dysphagia), heartburn sensation, regurgitation or acid reflux, dry cough, sore throat, and chest pain.

GERD is believed to be caused by the overuse of certain medications, such as calcium channel blockers, nitrates and antihistamines. Unhealthy lifestyle factors such as smoking, drinking, slouching, consuming caffeinated drinks, eating large meals, and sleeping immediately after eating are some other typical causes for the occurrence of GERD. Pharmaceutical agents that are used to prevent complications and reduce morbidity in patients with GERD include antacids, H2 receptor antagonists, proton pump inhibitors (PPIs), and prokinetic agents.

Technavio’s analysts forecast the global GERD drugs market to grow at a CAGR of 2.85% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global GERD drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of various drug classes used in the treatment of GERD.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • Europe
Technavio's report, Global GERD Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AstraZeneca
  • Eisai
  • GlaxoSmithKline
  • Johnson & Johnson
  • Takeda
Other prominent vendors
  • Ahn-Gook Pharmaceutical
  • Cancer Advances
  • CJ Cheil Jedang
  • Daewoong Pharmaceutical
  • Ironwood Pharmaceuticals
  • RaQualia Pharma
  • SFJ Pharmaceuticals Group
  • Sucampo Pharmaceuticals
  • Vecta Pharmaceuticals
  • Wockhardt
  • Yuhan
  • Zeria Pharmaceutical
Market driver
  • Unmet medical needs
  • For a full, detailed list, view our report
Market challenge
  • Increased preference for CAM
  • For a full, detailed list, view our report
Market trend
  • Increase in awareness about GERD
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global GERD Market 2016-2020

Technavio recognizes the following companies as the key players in the Global GERD Market: AstraZeneca, Eisai, GlaxoSmithKline, Johnson & Johnson and Takeda.

Other Prominent Vendors in the market are: Ahn-Gook Pharmaceutical, Cancer Advances, CJ Cheil Jedang, Daewoong Pharmaceutical, Ironwood Pharmaceuticals, RaQualia Pharma, SFJ Pharmaceuticals Group, Sucampo Pharmaceuticals, Vecta Pharmaceuticals, Wockhardt, Yuhan, and Zeria Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “Awareness among individuals about GERD is increasing, and there are various therapies available for its treatment. This would increase the number of treatment-seeking patients, thus giving rise to the overall consumption of related drugs. Similarly, strategic alliances among vendors to consolidate their positions in the market are also expected to exert a positive influence on the market during the forecast period.”

According to the report, the global GERD drugs market is driven the presence of huge unmet medical need in GERD. The lack of FDA approved drugs and the usage of generics and off-label drugs are causing market share erosion of prescription products. Thus, for drug makers, this presents an opportunity to develop therapies that can give them an edge over others to grab a major share of the total GERD drugs market.

Further, the report states that the use of complementary and alternative treatments by patients is a major challenge for the global GERD drugs market.

Companies Mentioned

AstraZeneca, Eisai, GlaxoSmithKline, Johnson & Johnson, Takeda, Ahn-Gook Pharmaceutical, Cancer Advances, CJ Cheil Jedang, Daewoong Pharmaceutical, Ironwood Pharmaceuticals, RaQualia Pharma, SFJ Pharmaceuticals Group, Sucampo Pharmaceuticals, Vecta Pharmaceuticals, Wockhardt, Yuhan, Zeria Pharmaceuticals.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
    • Product profiles
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Disease overview
    • Understanding the disease
    • Types of GERD
    • Signs and symptoms
      • Table Symptoms of pediatric GERD
      • Table GERD symptoms of older children and adolescents
    • Risk factors
      • Table Common risk factors for GERD
    • Diagnosis
    • Treatment
      • Table Dose, frequency, and average generic prices
      • Table Alternative treatment for GERD
      • Table Time line of the US FDA approved drugs for the treatment of GERD
    • Usage of OTC drugs in GERD
      • Table Comparison between prescription and OTC drugs
      • Table Advantages and disadvantages of OTC drugs
    • Epidemiology
    • Economic burden
  • Pipeline portfolio
    • Table Pipeline molecules for GERD
    • Table GERD clinical trials by development phase
    • Table GERD clinical trials by trial status
    • Information on pipeline candidates
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global GERD drugs market 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Table Global GERD drugs market segmentation by drug class
    • Table Global GERD drugs market segmentation by drug class 2015
  • Global antacids market
    • Introduction
    • Market overview
      • Table Global antacids market 2015-2020 ($ billions)
  • Global PPI drugs market
    • Introduction
    • Market overview
      • Table PPI sales in major non-US markets 2013 ($ millions)
      • Table Global PPIs market 2015-2020 ($ billions)
  • Global H2 receptor antagonist drugs market
    • Introduction
    • Market overview
      • Table Global H2 receptor antagonists market 2015-2020 ($ billions)
  • Market segmentation by route of administration
    • Table Global GERD drugs market segmentation by route of administration
    • Oral
    • Parenteral
  • Market segmentation by dosage form
    • Table Global GERD drugs market segmentation by dosage form
    • Solid
    • Liquid
  • Geographical segmentation
    • Global GERD drugs market segmentation by geography
      • Table Global GERD drugs market by geography 2015
      • Table Global GERD drugs market by geography 2015-2020 ($ billions)
    • GERD drugs market in the Americas
      • Table GERD drugs market in the Americas 2015-2020 ($ billions)
    • GERD drugs market in EMEA
      • Table GERD drugs market in EMEA 2015-2020 ($ billions)
    • GERD drugs market in APAC
      • Table GERD drugs market in APAC 2015-2020 ($ billions)
  • Market drivers
    • Lifestyle factors
    • Overuse of medicines and dietary supplements
    • Unmet medical needs
    • Increase in prevalence of GERD
    • Cost-effective OTC drugs
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Increased preference for CAM
    • Adverse effects of drugs
      • Table Common side effects associated with Nexium, Prontonix, Aciphex, and other heartburn medications
    • Generic erosion
    • Counterfeit drugs
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Self-medication
      • Table Drugs that underwent Rx-to-OTC switch in the US
    • Increase in awareness about GERD
    • Intense competition
    • Strategic alliances
  • Vendor landscape
    • Competitive scenario
  • Key vendor analysis
    • AstraZeneca
      • Table AstraZeneca: Business segmentation by revenue 2014
      • Table AstraZeneca: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table AstraZeneca: Geographical segmentation by revenue 2014
      • Table AstraZeneca: YoY revenue growth of Nexium 2012-2014 ($ billions)
      • Table AstraZeneca: YoY revenue growth of Losec 2012-2014 ($ millions)
      • Table AstraZeneca: YoY revenue growth of Vimovo 2012-2014 ($ millions)
      • Table AstraZeneca: Key takeaways
    • Eisai
      • Table Eisai: Business segmentation by revenue 2014
      • Table Eisai: Business segmentation by revenue 2013 and 2014 ($ millions)
      • Table Eisai: YoY revenue growth of Pariet 2011-2014 ($ billions)
      • Table Eisai: Key takeaways
    • GSK
      • Table GSK: Business segmentation by revenue 2014
      • Table GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table GSK: Geographical segmentation by revenue 2014
      • Table GSK: Key takeaways
    • Johnson & Johnson
      • Table Johnson & Johnson: Business segmentation by revenue 2014
      • Table Johnson & Johnson: Business segmentation 2013 and 2014 by revenue ($ billions)
      • Table Johnson & Johnson: Geographical segmentation by revenue 2014
      • Table Johnson & Johnson: Key takeaways
    • Takeda
      • Table Takeda: Business segmentation by revenue 2014
      • Table Takeda: Business segmentation by revenue 2013 and 2014 ($ millions)
      • Table Takeda: Geographical segmentation by revenue 2014
      • Table Takeda: YoY revenue growth of Prevacid 2012-2014 ($ billions)
      • Table Takeda: YoY revenue growth of Dexilant 2012-2014 ($ billions)
      • Table Takeda: YoY revenue growth of Protonix 2012-2014 ($ billions)
      • Table Takeda: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report